Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02847975 · ClinicalTrials.gov registry record · Phase 1
Sodium Nitrate to Improve Blood Flow
A Phase 1 study of Becker Muscular Dystrophy, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT02847975: Completed Phase 1 study of Becker Muscular Dystrophy, sponsored by Cedars-Sinai Medical Center.
NCT02847975 is a Phase 1 study of Becker Muscular Dystrophy that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 11 participants, below the 1,395-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02847975, a Phase 1 study of Becker Muscular Dystrophy, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigators recently showed that tadalafil restores functional sympatholysis in patients with Becker muscular dystrophy (BMD). If tadalafil restores functional sympatholysis in BMD via the NO-cyclic guanosine monophosphate pathway, then functional sympatholysis should also be restored by sodium nitrite- which is an indirect nitric oxide donor.
Primary Outcome
The pre-specified primary outcome is the pre vs. post treatment change in functional sympatholysis measured by muscle oxygenation.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Sodium nitrate
Study Locations (2)
California
- Cedars-Sinai Heart Institute - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT02847975 record still lists
NCT02847975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,395-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Becker Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Sodium nitrate is the first listed.
NCT02847975 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02847975 about?
NCT02847975 is a clinical study titled "Sodium Nitrate to Improve Blood Flow". Investigators recently showed that tadalafil restores functional sympatholysis in patients with Becker muscular dystrophy (BMD). If tadalafil restores functional sympatholysis in BMD via the NO-cyclic guanosine monophosphate pathway, then functional sympatholysis should also be restored by sodium ni...
What is the current status of trial NCT02847975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-10. Estimated completion is 2014-12.
What conditions does trial NCT02847975 study?
This clinical trial studies the following conditions: Becker Muscular Dystrophy.
What interventions are being tested in trial NCT02847975?
The interventions under investigation include: Sodium nitrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02847975?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02847975 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Becker Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02847975's enrollment target sits among peer trials
11 12th of 12 higher than 1 of 12 other Becker Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Becker Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
COMPLETED · Phase 1
-
Gentamicin Treatment of Muscular Dystrophy
COMPLETED · Phase 1
-
The Duchenne Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
RECRUITING
-
CureDuchenne Link®: A Resource for Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia